Skip to main content
Figure 2 | Radiation Oncology

Figure 2

From: Elective lymph node irradiation late course accelerated hyper-fractionated radiotherapy plus concurrent cisplatin-based chemotherapy for esophageal squamous cell carcinoma: a phase II study

Figure 2

Kaplan-Meier curve of overall survival (OS) for whole group patients treated with late course accelerated hyper-fractionated radiotherapy plus concurrent chemotherapy. With a median follow-up of 18.5 months, the median survival was 34.4 months (95% confidence interval: 19.1–49.6 months), and the 1-, 3-, 5-year OS were 75.5%, 46.5%, 22.7%, respectively.

Back to article page